We present the case of a patient with oral squamous cell carcinoma treated with the programmed death ligand inhibitor, pembrolizumab, an immune checkpoint inhibitor. She subsequently developed vasovagal-type autonomic dysfunction thought to be secondary to the pembrolizumab. The patient's vasovagal symptoms resolved with the initiation of oral glucocorticoids.
Keywords: Cancer - see Oncology; Cancer intervention; Cardiovascular system.
© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.